Abstract
Grand challenges in diabetes.
Highlights
In the treatment of diabetes, we have come a long way from the once dearth of agents that at one time included only insulin, sulfonylureas and the biguanides
Less than one third of patients with diabetes are at their management targets of their glycemic control, a number which plummets further to
Three major studies – ADVANCE, ACCORD, and VADT – taught us that intensification of glycemic control in people at great risk for macrovascular complications does not achieve a reduction in major adverse cardiovascular events (MACE; Boussageon et al, 2011; Bennett et al, 2012)
Summary
In the treatment of diabetes, we have come a long way from the once dearth of agents that at one time included only insulin, sulfonylureas and the biguanides. Less than one third of patients with diabetes are at their management targets of their glycemic control, a number which plummets further to
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
